bioRxiv · 10.1101/2021.01.26.426986
Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum
Abstract
We performed the plaque reduction neutralization test (PRNT50) using sera collected from the 26 recipients of BBV152/COVAXIN against hCoV-19/India/20203522 (UK-variant) and hCoV27 19/India/2020Q111 (heterologous strain). A comparable neutralization activity of the vaccinated individuals sera showed against UK-variant and the heterologous strain with similar efficiency, dispel the uncertainty of possible neutralization escape.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Sapkal, G. N., Yadav, P., Ella, R., Deshpande, G., Sahay, R., Gupta, N., Mohan, V. K., Abraham, P., Panda, S., Bhargava, B.. 2021-01-26. Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum. https://doi.org/10.1101/2021.01.26.426986
Cite the original work for its findings. Save a collection to share your selection of sources.